Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Akero Therapeutics, Inc. AKRO
$45.41
-$0.19 (-0.42%)
На 18:01, 12 мая 2023
+10.11%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2133892530.00000000
-
week52high
54.88
-
week52low
7.52
-
Revenue
0
-
P/E TTM
-19
-
Beta
-0.94165800
-
EPS
-2.89000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 15 ноя 2021 г. |
| Morgan Stanley | Equal-Weight | Overweight | 19 окт 2021 г. |
| B of A Securities | Buy | 10 сент 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 16 авг 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 14 сент 2022 г. |
| Evercore ISI Group | Outperform | In-Line | 14 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 07 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
| Morgan Stanley | Overweight | Equal-Weight | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cheng Andrew | D | 160868 | 25000 | 01 февр 2023 г. |
| Cheng Andrew | D | 370999 | 2000 | 01 февр 2023 г. |
| Cheng Andrew | D | 372999 | 8155 | 01 февр 2023 г. |
| Cheng Andrew | D | 381154 | 14845 | 01 февр 2023 г. |
| Cheng Andrew | A | 395999 | 25000 | 01 февр 2023 г. |
| Yale Catriona | D | 81268 | 1105 | 13 янв 2023 г. |
| Yale Catriona | D | 82373 | 1313 | 13 янв 2023 г. |
| Yale Catriona | D | 83686 | 1534 | 13 янв 2023 г. |
| Yale Catriona | D | 85220 | 1048 | 13 янв 2023 г. |
| Lamy Patrick | D | 100000 | 100000 | 10 янв 2023 г. |
Новостная лента
Akero Therapeutics: Proof Of Concept With EFX, Sets Up Catalyst Opportunities In 2023
Seeking Alpha
09 мая 2023 г. в 04:37
Akero Therapeutics has a proof of concept in using EFX for the treatment of patients with NASH Fibrosis established in the phase 2b HARMONY study. Results from cohort D of phase 2b SYMMETRY study using EFX on top of existing GLP-1 receptor agonist therapy to treat patients with pre-cirrhotic NASH and T2D expected Q2 2023.
Akero Therapeutics: Excellent Data, Solid Clinical Potential, No Major Near Term Catalysts
Seeking Alpha
07 мая 2023 г. в 10:05
AKRO will produce phase 2b SYMMETRY data in 4Q, but phase 3 will be a few years away. I believe Madrigal's success and the far off phase 3 may dampen exuberance around SYMMETRY.
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
Seeking Alpha
29 мар 2023 г. в 23:40
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
Investors Business Daily
22 мар 2023 г. в 09:14
Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared first on Investor's Business Daily.
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
04 янв 2023 г. в 08:00
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.